一箭双雕：淋巴瘤和 HIV 的潜在联合治疗方案。

One arrow for two targets: potential co-treatment regimens for lymphoma and HIV.

机构信息

Department of Infectious Diseases, Beijing You An Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing Key Laboratory for HIV/AIDS Research, Beijing 100069, China.

Department of Hematology, Nanjing Medical University Affiliated Nanjing First Hospital, Nanjing, Jiangsu, China.

出版信息

Blood Rev. 2022 Sep;55:100965. doi: 10.1016/j.blre.2022.100965. Epub 2022 Apr 23.

DOI:10.1016/j.blre.2022.100965

PMID:35489964

Abstract

In 2007, an HIV-infected individual (Berlin patient) underwent two allogeneic haematopoietic stem cell transplantations (allo-HSCTs) from a donor with a homozygous mutation in the HIV co-receptor CCR5 (CCR5Δ32) for the treatment of acute myeloid leukaemia, which eradicated HIV from infected patients simultaneously. Ten years later, another success in the 'London patient' was reported. These two cases suggest that allo-HSCT from a suitable donor is feasible for the treatment of haematological malignancies and HIV. Moreover, other novel approaches for anti-lymphoma have effectively suppressed HIV replication, including chimeric antigen receptor T-cell (CAR-T) immunotherapy, PD-1/Programmed death-ligand-1 (PD-L1) blockade, and therapies based on mechanisms that target the critical molecular pathways of tumour. This review discusses these approaches for both lymphoma and anti-HIV therapy.

摘要

2007 年，一名 HIV 感染者（柏林患者）接受了来自具有 HIV 辅助受体 CCR5 （CCR5Δ32）纯合突变供体的两次同种异体造血干细胞移植（allo-HSCT），用于治疗急性髓系白血病，同时从受感染患者中根除了 HIV。十年后，又报道了另一位“伦敦患者”的成功案例。这两个案例表明，来自合适供体的 allo-HSCT 可用于治疗血液系统恶性肿瘤和 HIV。此外，其他新型抗淋巴瘤方法也有效地抑制了 HIV 复制，包括嵌合抗原受体 T 细胞（CAR-T）免疫疗法、PD-1/程序性死亡配体-1（PD-L1）阻断以及基于靶向肿瘤关键分子途径的治疗方法。本综述讨论了这些用于淋巴瘤和抗 HIV 治疗的方法。